BioCryst halts en­roll­ment in all stud­ies for its lead pipeline can­di­date — shares crash

BioCryst is tak­ing a beat­ing Fri­day morn­ing af­ter re­port­ing it would pause en­roll­ment in three stud­ies for its lead pipeline pro­gram.

In a terse state­ment put out right be­fore the mar­ket opened, the Durham, NC-based biotech said it dis­cov­ered el­e­vat­ed serum cre­a­ti­nine lev­els in some pa­tients, and will halt re­cruit­ment while it in­ves­ti­gates. El­e­vat­ed cre­a­tine lev­els can be a sign of kid­ney dys­func­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.